The devastating impact of respiratory infections highlights the critical need for novel prophylactic vaccines. The COVID-19 experience underscored the power of vaccines in mitigating the clinical consequences of such infections and demonstrated the immense effort required to develop safe and effective vaccines. This chapter emphasizes the importance of bacterial immunotherapies as a complementary tool in our fight against respiratory infections. These immunotherapies activate various immunological mechanisms, with trained immunity (TI) being particularly significant. This concept leads to trained immunity-based vaccines (TIbVs), which represent a novel approach in vaccinology. TIbVs aim to generate broad, long-lasting innate immune responses and enhance the immunogenicity of existing antigen-specific vaccines. Examples discussed in this chapter include the tuberculosis vaccine BCG and the polybacterial immunotherapy MV130, illustrating how TIbVs can offer protection against a wide range of respiratory infections. Notably, TIbVs can be used alongside current vaccines or against pathogens lacking specific vaccines.